Cheminformatics approaches such as Quantitative Structure Activity Relationship (QSAR) modeling have been used traditionally for predicting chemical toxicity. In recent years, high throughput biological assays have been increasingly employed to elucidate mechanisms of chemical toxicity and predict toxic effects of chemicals in vivo. The data generated in such assays can be considered as biological descriptors of chemicals that can be combined with molecular descriptors and employed in QSAR modeling to improve the accuracy of toxicity prediction. In this review, we discuss several approaches for integrating chemical and biological data for predicting biological effects of chemicals in vivo and compare their performance across several data sets. We conclude that while no method consistently shows superior performance, the integrative approaches rank consistently among the best yet offer enriched interpretation of models over those built with either chemical or biological data alone. We discuss the outlook for such interdisciplinary methods and offer recommendations to further improve the accuracy and interpretability of computational models that predict chemical toxicity.
INTRODUCTION
Predictive toxicology is often evaluated at the initial stages of regulatory assessment of environmental chemicals or drug discovery to prioritize high-risk chemicals for further testing or eliminate such chemicals from further consideration, respectively. In the current age of chemical innovation, hundreds to thousands of new chemicals are introduced each year [1] creating an urgent need to substantially optimize testing resources and reduce animal use. Current toxicity evaluation protocols increasingly follow a tiered approach where chemicals are funneled through in silico, in vitro and in vivo tests in order of decreasing throughput [2] [3] [4] . Among the in silico methods, cheminformatics and bioinformatics have been established as integral parts of toxicity testing, especially at the initial stages.
Most of the current computational tools employed in toxicity assessment rely either on chemical or biological data. Specifically, cheminformatics approaches attempt to predict toxicity from chemical structure alone while ignoring the underlying complex biological mechanisms whereas bioinformatics approaches ignore the inherent structural features of chemical molecules that may enrich and improve modeling outcomes. In contrast, integrative chemical-biological modeling may both improve the prediction performance of models and uncover insights previously invisible to either informatics discipline alone. The realization that chemical and biological entities interact at various levels of organization in the body has spawned the emerging fields of systems chemical biology [5] [6] [7] , systems toxicology [8] , or systems pharmacology [9] [10] [11] [12] . Several recent reviews [6, 10, [12] [13] [14] [15] [16] have focused on the current state of each individual discipline and proposed general schemes to integrate cheminformatics and bioinformatics approaches for improved understanding of chemical effects on biological systems. Few integrative studies, however, have been reported; their paucity is stemming from the lack of both suitable data and integrative methods. Nevertheless, a new data landscape for predictive toxicology has emerged due to new toxicity testing paradigms such as REACH (Registration, Evaluation and Authorization of CHemicals) [17] and Toxicity Testing for the 21 st Century [18] . These programs have stimulated the proliferation of short-term biological assays employed for testing of growing collections of chemicals [19] . These transformative experimental programs offer new opportunities for data-driven learning beyond the traditional methods of cheminformatics or bioinformatics.
In this review, we reiterate the case for integrative chemical-biological approaches for predicting chemical effects in vivo with the ultimate goal of developing safer pharmaceutical or industrial chemicals. We assess the strengths and limitations of current predictive toxicology efforts based on either cheminformatics or bioinformatics and then discuss studies drawing from the two disciplines concurrently. Lastly, we put forth our vision for such interdisciplinary methods and offer recommendations to further improve the accuracy and interpretability of chemical toxicity prediction models.
CHEMINFORMATICS IN TOXICITY PREDICTION
The availability of large toxicity datasets including hundreds, even thousands of chemicals tested as part of ToxCast [20] and Tox21 [21] projects has re-established an interest in cheminformatics as a powerful computational approach for predicting chemical toxicity. In particular, Quantitative Structure-Activity Relationships (QSAR) modeling is often used as a first-line tool for toxicity prediction [22] given that it requires the knowledge of molecular structure only. The first QSAR study was published in 1962 [23] ; it employed regression model correlating plant growth to molecular electronic parameters. Since then, QSAR has grown in sophistication to incorporate thousands of chemical descriptors and machine learning methods. Despite its popularity, QSAR modeling has been criticized for poor predictivity and interpretability [24] [25] [26] [27] . Measures to address weaknesses include OECD guidelines [28] and implementation of best practices [29] which advocate careful data curation [30] and processing [31] , representative sampling of the chemical space [32] , stringent validation [33] and rational descriptor selection driven by a mechanistic basis to simplify interpretation [26] .
Despite the above measures, cheminformatics-based prediction of complex toxic phenomena has fallen short of expectations. In reality, the relationship between chemical structures and toxicity is far more circuitous than the models assume, involving many non-chemical factors, e.g., those dependent on complex biological mechanisms. The significance of these non-chemical factors depends on the prediction target. Generally, QSAR models are more successful at predicting direct chemical-induced outcomes (e.g., mutagenicity) than those farther downstream of chemical-initiating events (e.g., carcinogenicity) [34] . Indeed, in some cases when large datasets are available, e.g., for mutagenicity (that largely depends on molecular interactions between chemical and DNA) the QSAR model accuracy approaches that of the experimental Ames assay [34, 35] . On the contrary, carcinogenicity has been notoriously difficult to predict because of its heterogeneous modes of action and the biological host's adaptive capacity for recovery [34] . One way to account for complex biological mechanisms underlying many in vivo effects and achieve better modeling outcomes is to integrate multiple biological characteristics of chemicals obtained in short term assays with inherent chemical properties of compounds. This emerging integrative modeling approach at the interface between bio-and cheminformatics is the main theme of this review.
BIOINFORMATICS IN TOXICITY PREDICTION
The post-genome era saw a dramatic rise of bioinformatics. While the field of bioinformatics is broad, involving the computational analysis of biological information arising from the detailed characterization of an organism at various levels (molecular, cellular, tissue, organ, system), this section focuses on applying bioinformatics approaches in toxicology where the goal is to study multiple biological perturbations in response to chemical insult.
Simultaneously studying thousands of bioassays offers several advantages: key biomarkers can be quickly identified and interactions between the biomarkers characterized, allowing for a systems toxicology approach. In drug discovery, the use of diverse bioassay panels helps to quickly identify potentially toxic properties (e.g., cytochrome P450 inhibition, transporter blockage) which may provide clues into the pathogenesis of undesired effects caused by a compound. The bioassay signatures of compounds reflecting certain toxic modes of action may be used to probe for compounds with similar mode of action. An example of broad biological characterization of drugs is provided by the Japanese Toxicogenomics Project where toxicogenomic signatures representative of various types of hepatotoxicities (e.g. phospholipidosis, glutathione depletion) have been determined [36] . These signatures can be generated for new drugs or drug candidates to predict their longterm toxicities.
Advances in assay technology have given rise to a diversity of biological measurements such as 'omics signatures, enzymatic activity, receptor binding affinity, cytotoxicity, and histology imaging, allowing toxicologists to probe into both microscopic and macroscopic changes in the body. These bioassays may have different predictive power depending on the experimental error and biological relevance. High-dimensional 'omics' data, especially transcriptomics, were shown to predict long term effects such as hepatic tumorigenicity with high accuracy [37] [38] [39] [40] . In contrast, hundreds of bioassays capturing a large diversity of biological characteristics in ToxCast Phase I [41, 42] , were less predictive [43] . Reasons cited by the authors include inadequate experimental fidelity, inadequate biological relevance, and poor interspecies extrapolation.
Certain successes notwithstanding, the use of biological data and bioinformatics approaches in chemical toxicity prediction is not problem-free. The ease of collecting large-scale bioassay data has encouraged fishing expeditions where assays often produce poor quality results or may be irrelevant to any toxicity leading to false discoveries. Overly sensitive 'omics' markers may be producing more noise than signal [44] . Countermeasures include proper statistical correction (e.g. Bonferroni, Holm) and proper application of biological context to draw meaningful conclusions from the data.
The focus on biological information has also regrettably overlooked another important dimension of toxicology: chemical information. While bioassays were previously performed for a few chemicals due to throughput limitations, it is now possible to perform high throughput screening (HTS) for large chemical libraries [45] . Consequently, in vitro toxicity data is rich in both biological and chemical information. The underlying chemical patterns, a traditional and rich source of data in cheminformatics, have not been capitalized upon by bioinformatics. A reasonable approach may be to combine bioinformatics and cheminformatics approaches for improved toxicity prediction.
INTEGRATIVE APPROACH COMBINING CHEMINFORMATICS AND BIOINFORMATICS
Given the lack of consideration of biological factors in cheminformatics and ignorance of chemical structures in bioinformatics, the concurrent study of both biological and chemical domains may reveal new discoveries not possible with either domain alone. Such integrated approaches recognize that in vivo effects, whether occurring at the cellular, or systemic level, emerge from a complex interplay between the chemical inducer and the biological host. Chemical factors govern the molecular interactions between the chemical and its protein targets. These molecular interactions then initiate a cascade of interactions within the cell, organ or organism, eventually giving rise to the observed phenotype as a response to the chemical action on the biological system.
The rise of several recent enabling trends facilitates chemical-biological integration. First, there is an increased demand and acceptance of toxicity prediction from in silico and in vitro tests instead of in vivo tests in efforts to boost testing throughput, improve animal welfare and deepen our understanding of the toxicological mechanisms; these new paradigms are accelerated by regulatory programs such as REACH [17] and Toxicity Testing for the 21 st Century [18] . Consequently, in large-scale programs such as ToxCast [20] , Tox21 [21] , and Molecular Libraries Initiative [46] thousands of chemicals are tested in thousands of biological assays, with the results of these HTS studies placed in publicly available repositories such as PubChem [47] or ToxNet [48] . For instance, toxicity databases now contain large amounts of chemical and biological information through data consolidation (e.g. ACToR [19] , Bio2RDF [49] , OpenPHACTS [50] , PredPharmTox [51] ; see [11] for table of databases).
The unprecedented growth of data in terms of the number and diversity of chemicals, and comprehensive biological assay characterization has afforded new research opportunities for both cheminformatics and bioinformatics. Where previously only a few chemicals were tested, the new data landscape has reinvigorated interest in cheminformatics as a means of transforming latent chemical patterns into useful chemical insights. On the other hand, the deeper biological assay characterization allows one to learn more about each chemical in terms of underlying biological mechanisms of its in vivo effects. Yet, sticking to the approaches of only chemical or biological modeling is unlikely to take full advantage of the richness of the modern data streams that effectively capture chemical-biological interactions.
The many parallels between bioinformatics and cheminformatics provide points of commonality to facilitate integration. Underpinning both fields are statistical techniques relating molecular features of a chemical to its biological effects. These statistical relationships rely on the similarity principle which expects chemicals similar in their molecular feature profiles to exhibit similar behavior. The key difference between bioinformatics and cheminformatics here lies in the choice of appropriate molecular features, i.e., either 'omics' profiles assayed by HTS or molecular structural information represented by chemical descriptors. The statistical techniques, whether as simple as readacross or as complex as machine learning, are equally applicable to both fields.
A simple means of integration is to apply existing statistical methods to both chemical and biological types of molecular features. Another way is to merge chemical models with biological models. Other approaches may be less straightforward, strategically combining chemical structures and biological assays such that the two data sources compensate for each other's shortcomings and the complementary information between them is maximally used. Generally, modeling studies combining chemical and biological data have reported increased predictivity and interpretability (Table 1) . Integrative chemical-biological approaches attempted in those studies may be broadly classified into three types: 1) data pooling (Fig.  1A) , 2) model pooling (Fig. 1B) , or 3) other integrative strategies that exploit the multidomain data (e.g. hierarchical local models shown in Fig 1C) .
Data pooling
In data pooling, disparate data sources are pooled to create a larger, "hybrid" data matrix for modeling by existing statistical methods. This has been aided by the growing availability of consolidated databases. Besides HTS assays, new data streams can include text annotations automatically mined from biomedical literature (ChemoText [52] ), product labels (SIDER) [53] [54] [55] and clinical notes [56, 57] . Table 1 lists several studies predicting toxicity from pooling various data streams. Generally, prediction performance improved after pooling, although several exceptions exist. Among the exceptions, a comprehensive modeling of 60 in vivo toxicities based on chemical structures and/or in vitro assays of ToxCast phase I data described limited if any success with data pooling models [43] . Several other studies reported that models' accuracy dropped when chemical descriptors were added on top of bioassay data such as toxicogenomics [58] , hepatocyte imaging indicators [59] , and protein targets [60] . Noteworthy, all four of the mentioned studies [43, [58] [59] [60] employ rather small and structurally diverse sets of chemicals. Understandably, chemical models performed worse than biological ones [58] [59] [60] , while in the ToxCast study [43] both were similarly poor. Thus, we caution against favoring either chemical or biological model as either performance will depend on many contributing factors such as the size and structural diversity of the chemical datasets and quality of biological data. Where biological data included considerable noise, additional data treatment may improve prediction outcomes from data pooling. For example, Sedykh et. al. [61] introduced a noise filter to transform cytotoxicity profiles into dose-response curve parameters that, when pooled with chemical structures, provided more accurate models of rat acute toxicity than the original cytotoxicity assay values.
Model pooling
Another way of integrating chemical and biological data is by meta-analysis or ensemble modeling, which pools individual predictions from several models into a final predicted value. The main benefit of ensemble modeling, i.e., increased predictivity, arises when the constituent models compensate for the errors of one another [62] . The notion that many models are better than one is best exemplified by the random forest algorithm which seeks the consensus vote of numerous constituent decision tree models within its "forest" [63] . In the case of toxicity modeling, chemical-based models and biological-based models may be pooled such that their consensus vote provides the final prediction outcome.
Such model pooling is already widely practiced in regulatory chemical risk assessment and drug discovery during where all the prediction outcomes from various toxicity models are weighted before arriving at a consensus decision [64, 65] . For example, drugs must not contain structural alerts of mutagenicity and their bioassay profiles must indicate the lack of inhibitory effects on the major cytochrome P450 enzymes required for drug metabolism.
Ensemble modeling can be used in one of two ways. One approach is to require that all the constituent models for a compound point to the same prediction outcome so that the end point toxicity can be estimated with higher confidence. Alternatively, one can argue that ensemble modeling enlarges the modelable space of molecules such that compounds that cannot be predicted with confidence by one model receive their prediction from another model. In the first case, Vilar et. al. showed increased precision when a chemical similarity model was pooled with a model based on clinical notes [66, 67] . In the second case, an ensemble chemical-biological model may compensate for the invalid predictions by the QSAR model outside its chemical coverage area. However, ensemble models may not always outperform their constituent chemical and biological models, as we have demonstrated recently using four different data sets [68] . Especially where a constituent model is already highly predictive, adding another inferior model may lead to reduced predictive power of the consensus model. Thus, model pooling should be done with care paying attention to relative predictive power of each constituent model.
Other integrative methods
The mixed success of pooling data or models has led to the development of innovative approaches that leverage prior knowledge of the data structure and optimize the use of the disparate data sources. Network modeling that allows the simultaneous study of disparate entities (chemicals, targets and phenotypes) is employed increasingly [69] . In a graph representation (Figure 2) , entities appear as nodes connected by edges if they are associated. Association may be defined in terms of direct physical interaction (e.g., drug binds to target) or statistically (e.g., disproportionately more reports of adverse effect with drug). In such way modeling, the goal is to infer new associations among pairs of entities through indirect associations. This is best illustrated by Swanson's ABC paradigm [70] in which association between entities A and C is inferred if there exist direct associations between pairs A-B and B-C (Figure 2A ). Networks may be further enriched by chemical similarity [71, 72] , protein sequence similarity [73] , or side effect similarity [74] such that novel inferences with higher confidence can be drawn ( Figure 2B [75] ). Associations successfully predicted in recent studies include those of phenotype-target [72] , chemical-phenotype [76, 77] , and chemicaltarget [74, 78, 79] type. For examples of broader efforts to infer more than a single type of associations, the readers are referred to several recent studies [69, 71, 80] .
Strategic use of biological data to stratify data sets into distinct clusters for further separate or localized modeling can be a promising direction. Zhu et. al. [81] described a two-step hierarchical approach, in which the authors first stratified compounds by their in-vitro/invivo correlation into two classes , i.e., a group of compounds whose in vitro/in vivo data correlated and a remaining group where no correlation was observed. The authors then built a classification model using this biologically-inferred strata and then also built stratumspecific QSAR models. It has been shown that such a hierarchical workflow where a new compound was first assigned to one of the two strata followed by the prediction using stratum-specific models afforded overall improved prediction accuracy [81, 82] . Other strategic use of biological data to stratify data sets into clusters for localized modeling was also attempted by Lounkine et al. [83] who clustered compounds by chemical similarity and their bioactivity. Analogously, chemical structural data can provide useful input for biological modeling. For example, pharmacokinetics parameters, where unknown, may be estimated by QSAR models from molecular structure and then used in subsequent physiological-based models to simulate chemical toxicity in the body [84] [85] [86] .
Another recently published novel integrative method, quantitative chemical-biological readacross (CBRA) [68] , relied on the principles of k nearest neighbors. The CBRA approach can be viewed as an ensemble model, in which chemical-and biological-based predictions for a new chemical are weighted by similarity to known both chemical and biological analogs. This enhanced pooling of chemical and biological neighbors helps to maximize the complementarities between chemical and biological data. In particular, conflicting predictions from chemical and biological models are resolved, resulting in overall predictivity gains. The authors compared CBRA with two other types of integrative approaches (data pooling, model pooling) on four data sets and found that none of the three approaches was markedly superior to others. We believe that this holds true in general, and no single integrative technique is likely to solve all modeling problems. Instead, this we emphasize the importance of employing set of modeling tools from which most appropriate and expedient ones can be selected and attempted for each complex dataset.
RECOMMENDATIONS AND OUTLOOK
The mixed success of using both chemical and biological features suggest the following methodological implications for predicting chemical effects. First, consider information-rich and biologically relevant assays as features. Information-rich assays such as gene expression may have more predictive value than non-descript assays measuring binary biological responses (e.g., binding/nonbinding to a target protein) [87] . The bioassays may be selected rationally according to biological pathways to reflect their relevance to the in vivo effect [43, 88] . Third, careful variable selection [43] , modeling and validation according to OECD (Q)SAR principles [28] are necessary to ensure robust and accurate models [29] . Lastly, consider the choice of modeling methods. Irrelevant variables may affect some classification methods more than others. For example, instance-based methods including CBRA are more susceptible to irrelevant variables while others such as random forest can better tolerate noisy variables [89, 90] .
A multidisciplinary systems approach is increasingly seen as the key solution to translating molecular and preclinical insights into desired clinical outcomes of drug use. In addition to addressing the issue of data quality, further gains through methodological innovations and cohesive integration of the various disciplines will be necessary. Scientists who develop and employ such approaches need to have profound understanding of both the data and dataanalytical techniques. The ingredients for such multi-disciplinary efforts are unlikely to occur organically and will require deliberate efforts to foster a collaborative environment. As more data come online and advances in assay technologies reduce experimental variability, we expect integrative approaches to play a greater role in toxicology and drug discovery applications. Knowledge-based relationships between objects (e.g., drugs, targets, and activity phenotypes) form an object network that allows new inferences. Table 1 Integrative approaches used for toxicity prediction
Prediction target Data sources Type Studies
Rat LD 50 Chemical structure, Cytotoxicity
Data pooling [91] Rat LD 50 Chemical structure, Dose-cytotoxicity profiles Data pooling [61] Rat LD 50 Chemical structure, Cytotoxicity
Integrative method [81] Rat reproductive toxicity Chemical structure, In vitro assays
Integrative method [82] Drug hepatotoxicity Chemical structure, Transcriptomics Integrative method [93] Curr Top Med Chem. Author manuscript; available in PMC 2017 March 09.
